Cite
HARVARD Citation
Rozeman, E. et al. (2019). Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet oncology. 20 (7), pp. 948-960. [Online].